Search Result

Results for "

cognitive impairments

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (2) Aminopeptidase (1) AMPK (2) Amyloid-β (10) Apoptosis (4) Autophagy (1) Bcl-2 Family (2) Beta-secretase (1) Biochemical Assay Reagents (1) Caspase (1) CDK (3) Cholinesterase (ChE) (10) Dopamine Receptor (4) Endogenous Metabolite (1) Estrogen Receptor/ERR (1) Ferroptosis (1) GABA Receptor (1) GlyT (1) GSK-3 (1) HDAC (2) Histamine Receptor (2) Histone Acetyltransferase (1) iGluR (12) Influenza Virus (2) Integrin (1) Isotope-Labeled Compounds (2) mAChR (1) mGluR (1) Microtubule/Tubulin (1) MMP (1) Monoamine Oxidase (3) NF-κB (4) Orthopoxvirus (2) Oxidative Phosphorylation (2) p38 MAPK (2) Phosphodiesterase (PDE) (2) Prolyl Endopeptidase (PREP) (2) SARS-CoV (2) Serotonin Transporter (2) Sigma Receptor (2) Small Interfering RNA (siRNA) (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) VEGFR (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (63)

By Targets:

11β-HSD (2)

5-HT Receptor (2)

Aminopeptidase (1)

AMPK (2)

Amyloid-β (10)

Apoptosis (4)

Autophagy (1)

Bcl-2 Family (2)

Beta-secretase (1)

Biochemical Assay Reagents (1)

Caspase (1)

CDK (3)

Cholinesterase (ChE) (10)

Dopamine Receptor (4)

Endogenous Metabolite (1)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

GABA Receptor (1)

GlyT (1)

GSK-3 (1)

HDAC (2)

Histamine Receptor (2)

Histone Acetyltransferase (1)

iGluR (12)

Influenza Virus (2)

Integrin (1)

Isotope-Labeled Compounds (2)

mAChR (1)

mGluR (1)

Microtubule/Tubulin (1)

MMP (1)

Monoamine Oxidase (3)

NF-κB (4)

Orthopoxvirus (2)

Oxidative Phosphorylation (2)

p38 MAPK (2)

Phosphodiesterase (PDE) (2)

Prolyl Endopeptidase (PREP) (2)

SARS-CoV (2)

Serotonin Transporter (2)

Sigma Receptor (2)

Small Interfering RNA (siRNA) (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

VEGFR (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (63)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151518

Aminopeptidase-IN-1	Aminopeptidase	Neurological Disease
Aminopeptidase-IN-1 (compound 16o) is a potent insulin-regulated aminopeptidase (IRAP) inhibitor with an K_i value of 7.7 μM. Aminopeptidase-IN-1 can be used tor research cognitive and memory impairments .

HY-N7981

Pratensein	NF-κB	Neurological Disease
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .

HY-103405

NGD94-1	Dopamine Receptor	Neurological Disease
NGD94-1 is a specific dopamine D₄ receptor antagonist. NGD94-1 can effectively reverse Phencyclidine-induced cognitive impairment in marmosets. NGD94-1 can be used in the study of psychiatric diseases .

HY-19668A

SGS518 oxalate	5-HT Receptor	Neurological Disease
SGS518 oxalate is a selective 5-HT₆R antagonist. SGS518 oxalate can be used for the research of cognitive impairments such as amnesia, anxiety and depression, and it is effective in protecting mouse retina at high doses ^[1]

HY-W324220

11β-HSD1-IN-10	11β-HSD	Metabolic Disease
11β-HSD1-IN-10 (compound c3a) is a potent 11β-HSD1 inhibitor (IC₅₀=1.8 µM for human). 11β-HSD1-IN-10 can be used in studies of obesity, hyperglycemia and cognitive impairment .

HY-149473

AChE-IN-39	Cholinesterase (ChE)	Neurological Disease
AChE-IN-39 (Compound 7c) is an AChE inhibitor (IC₅₀: 0.058 μM). AChE-IN-39 has DPPH scavenging activity. AChE-IN-39 improves the cognitive impairment in AlCl₃-induced amnesia animal model. AChE-IN-39 can be used for research of Alzheimer's disease .

HY-163320

AChE/Aβ-IN-5	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .

HY-151386

BChE-IN-13	Cholinesterase (ChE)	Neurological Disease
BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .

HY-139973

OAB-14	Amyloid-β	Neurological Disease
OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .

HY-W324243

11β-HSD1-IN-9	11β-HSD	Metabolic Disease
11β-HSD1-IN-9 (compound c4a) is a potent 11β-HSD1 inhibitor with IC₅₀ values of 0.48 and 1.3 µM for human and murine 11β-HSD1, respectively. 11β-HSD1-IN-9 competitively interacts with rat 11β-HSD1. 11β-HSD1-IN-19 can be used in studies of obesity, hyperglycemia and cognitive impairment .

HY-121035

7BIO 7-Bromoindirubin-3-Oxime	CDK GSK-3	Neurological Disease
7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice ^[1].

HY-103157

PD146176 2 Publications Verification NSC168807	Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC₅₀=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-151389

BChE-IN-14	Cholinesterase (ChE)	Neurological Disease
BChE-IN-14 (compound 19c) is a selective butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 0.23 and 0.011 μM for eqBChE and hBChE, respectively. BChE-IN-14 shows good blood brain barrier permeation and primary cell safety. BChE-IN-14 is able to restore cognitive impairment in vivo, it can be used for the research of Alzheimer’s disease .

HY-146351

HDAC-IN-38	HDAC	Neurological Disease
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .

HY-156634

Risevistinel NYX-783	iGluR	Neurological Disease
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-156626

Nevadistinel NYX-458; NYX-3054	iGluR	Neurological Disease
Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-B1715

Oxiracetam ISF2522	GABA Receptor	Neurological Disease
Oxiracetam is a cyclic derivative of γ-aminobutyric acid (GABA) which has been commonly used as nootropic agent to treat cognitive impairments.

HY-10933

CX516 1 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-141832

mGluR5 modulator 1	mGluR	Neurological Disease
mGluR5 modulator 1 is a mGluR5 positive allosteric modulator. mGluR5 modulator 1 can be used for the research of the schizophrenia and cognitive impairments .

HY-111081C

(±)-PPCC oxalate	Sigma Receptor	Neurological Disease
(±)-PPCC oxalate is a sigma-1 agonist that mainly interacts with sigma-1 receptors with K_i of 1.5 nM. (±)-PPCC oxalate has effective anti-amnesia effects in rats with mild or severe cognitive impairment, and can improve the cognitive abilities of rats .

HY-N8903

Mumefural	Integrin NF-κB Toll-like Receptor (TLR) TNF Receptor	Cardiovascular Disease Neurological Disease
Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment .

HY-N2195

Nootkatone 1 Publications Verification (+)-Nootkatone
Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects . Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease .

HY-17455

Pramiracetam CI-879 free base	Prolyl Endopeptidase (PREP)	Neurological Disease
Pramiracetam (CI-879 free base) is a PREP (prolyl endopeptidase) inhibitor. Pramiracetam improves cognitive impairment caused by traumatic brain injury. Pramiracetam can be used in the study of neurodegenerative diseases .

HY-15114

S 17092 S 17092-1	Prolyl Endopeptidase (PREP)	Neurological Disease
S 17092 (S 17092-1) is a potent cerebral prolyl-endopeptidase (PEP) inhibitor with an IC₅₀ of 1.2 nM. S 17092 can be used for the research of memory impairment and cognitive disorders associated with cerebral aging .

HY-110176

ASP2535	GlyT	Neurological Disease
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .

HY-B0463

Clomiphene citrate 4 Publications Verification Clomifene citrate	Estrogen Receptor/ERR	Neurological Disease Endocrinology Cancer
Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .

HY-W166297

Esculin sesquihydrate	p38 MAPK	Cancer
Esculin sesquihydrate, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin sesquihydrate ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts anti?oxidative stress and anti?inflammatory effects, via the MAPK signaling pathway .

HY-N0045

Ginsenoside Rg1 Maximum Cited Publications 6 Publications Verification Panaxoside A; Panaxoside Rg1	Amyloid-β NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-10933S

CX516-d10 BDP 12-d₁₀	Isotope-Labeled Compounds iGluR	Neurological Disease
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].

HY-157326

hMAO-B-IN-6	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-6 (compound 17d) is a potent and selective inhibitor of hMAO-B with an IC₅₀ of 67.02 nM. hMAO-B-IN-6 significantly improves Scopolamine (HY-N0296)-induced cognitive impairment in AD mice .

HY-N4268

Tenuifoliside B	Others	Neurological Disease
Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .

HY-N7109

Erucic acid
Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia .

HY-19881

ABT-288
ABT-288 is a competitive, potent and selective histamine H3 receptor (H3R) antagonist. ABT-288 has K_i values of 1.9 and 8.2 nM for human and rat H3Rs, respectively. ABT-288 can be used in cognitive impairment research. .

HY-136093

Lixumistat hydrochloride HL271; IM156 hydrochloride; HL156A hydrochloride	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model . Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-155823

TZ4M	Cholinesterase (ChE)	Neurological Disease
TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .

HY-155822

TZ3O	Cholinesterase (ChE)	Neurological Disease
TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .

HY-114234A

TAK-070 Free base	Beta-secretase	Neurological Disease
TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC₅₀: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model .

HY-13340

VU0152100 VU152100	mAChR	Neurological Disease
VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia .

HY-136093A

Lixumistat acetate IM156; HL156A; HL271 acetate	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model . Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-149417

BChE/HDAC6-IN-1	HDAC Cholinesterase (ChE)	Neurological Disease
BChE/HDAC6-IN-1 is a potent and selective dual BChE/HDAC6 inhibitor with IC₅₀ values of 4 and 8.9 nM, respectively. BChE/HDAC6-IN-1 ameliorates the cognitive impairment in an Aβ1–42-induced mouse model and has the potental for AD research .

HY-N0045R

Ginsenoside Rg1 (Standard) Panaxoside A (Standard); Panaxoside Rg1 (Standard)	Amyloid-β NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Ginsenoside Rg1 (Standard) is the analytical standard of Ginsenoside Rg1. This product is intended for research and analytical applications. Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-14258A

Escitalopram oxalate 3 Publications Verification (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-14258

Escitalopram 3 Publications Verification (S)-Citalopram; (S)-(+)-Citalopram	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-N0188

Esculin 3 Publications Verification	p38 MAPK	Inflammation/Immunology Cancer
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-155484

SOMCL-668	Sigma Receptor	Neurological Disease
SOMCL-668 is a selective and potent sigma-1 receptor allosteric modulator. ?SOMCL-668 shows positive modulation of improvement in social deficits and cognitive impairment induced by the selective sigma-1 agonist PRE084.?SOMCL-668 displays anti-seizure activities and can be used for psychotic illness research .

HY-N0801

Polygalacic acid	MMP Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
Polygalacic acid, is a triterpene, isolated from the root of Polygala tenuifolia Willd. Polygalacic acid inhibits MMP expression. Polygalacic acid may have a therapeutic effect in Osteoarthritis (OA) treatment . Polygalacic acid exerts a significant neuroprotective effect on cognitive impairment, PA improves cholinergic system reactivity by inhibiting acetylcholinesterase (AChE) activity, increasing choline acetyltransferase (ChAT) activity, and elevating levels of acetylcholine (Ach) in the hippocampus and frontal cortex .

HY-148867

UCM-1306 2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-149984

MAO-B-IN-21	Monoamine Oxidase	Neurological Disease Inflammation/Immunology
MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model .

HY-116451

PF-04859989 hydrochloride 1 Publications Verification	Others	Neurological Disease
PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC₅₀s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .

HY-105066

Davunetide	Microtubule/Tubulin Amyloid-β	Neurological Disease
Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7981

Pratensein	Trifolium pratense L. Flavonoids Leguminosae Source classification Phenols Polyphenols Plants Isoflavones	NF-κB
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .

HY-N0045

Ginsenoside Rg1 Maximum Cited Publications 6 Publications Verification Panaxoside A; Panaxoside Rg1	Panax ginseng C. A. Meyer Triterpenes Structural Classification Neurological Disease Classification of Application Fields Anti-aging Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	Amyloid-β NF-κB Apoptosis
Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-N4268

Tenuifoliside B	Source classification Polygalaceae Phenols Polyphenols Plants Polygala tenuifolia Willd.	Others
Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .

HY-14258

Escitalopram 3 Publications Verification (S)-Citalopram; (S)-(+)-Citalopram	Natural Products Source classification Endogenous metabolite	Serotonin Transporter
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-N0045R

Ginsenoside Rg1 (Standard) Panaxoside A (Standard); Panaxoside Rg1 (Standard)	Panax ginseng C. A. Meyer Structural Classification Neurological Disease Classification of Application Fields Anti-aging Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	Amyloid-β NF-κB Apoptosis
Ginsenoside Rg1 (Standard) is the analytical standard of Ginsenoside Rg1. This product is intended for research and analytical applications. Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-N0188

Esculin 3 Publications Verification	Structural Classification Monophenols other families Classification of Application Fields Source classification Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Cancer	p38 MAPK
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-N0801

Polygalacic acid	Triterpenes Terpenoids Source classification Polygalaceae Plants Polygala tenuifolia Willd.	MMP Cholinesterase (ChE)
Polygalacic acid, is a triterpene, isolated from the root of Polygala tenuifolia Willd. Polygalacic acid inhibits MMP expression. Polygalacic acid may have a therapeutic effect in Osteoarthritis (OA) treatment . Polygalacic acid exerts a significant neuroprotective effect on cognitive impairment, PA improves cholinergic system reactivity by inhibiting acetylcholinesterase (AChE) activity, increasing choline acetyltransferase (ChAT) activity, and elevating levels of acetylcholine (Ach) in the hippocampus and frontal cortex .

HY-Y0966

Glycine 4 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite iGluR VEGFR Small Interfering RNA (siRNA)
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Cat. No.	Product Name	Chemical Structure

HY-W653905

Amantadine-d15 hydrochloride

Amantadine-d₁₅ hydrochloride is deuterated labeled Amantadine. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks